

CSANZ 2025 Image



Get more out of your CSANZ 2025 experience





# **Discover CSANZ 2025**

Welcome to the microsite for the Cardiac Society of Australia and New Zealand (CSANZ) Congress, held in Brisbane on 14-17 August 2025.

## **Novartis Sponsored Symposium and Mini Orals**

Details about the Novartis sponsored symposium and mini oral sessions during CSANZ.

Friday 15th August 2025

Novartis Breakfast Symposium: What Clinicians need to Know About Lp(a)

**Time:** 7:15am - 8:15am **Location:** Mezzanine 1

Novartis Lunch Symposium: Case Conversations: Clinical Case Reviews in

**Complex ASCVD** 

Time: 12:30pm - 1:30pm

Location: Plaza 3

Speakers: Dr John Amarena, Dr Melissa Leung

Saturday 16th August 2025

Novartis Mini Oral: A year on...What's new for lp(a)

Time: 10:00am - 10:30am Location: Theatrette 1

Novartis Mini Oral: "From Data to Action: ASCVD Audit Dashboard Review"

Novartis x Magentus Time: 3:00pm - 3:30pm Location: Theatrette 1 Speaker: Dr Andrew Roy

## **Novartis Dinner Meeting**

Register and find out more information about the Novartis CSANZ dinner meeting happening on Friday 15<sup>th</sup> August 2025

Date: Friday 15<sup>th</sup> August 2025

**Time:** 6:30 - 8:00pm

**Location:** "The Lex" Level 3, W Hotel Brisbane **Speakers:** Dr Nick Lan, A/Prof Adam Nelson

Chair: A/Prof Karam Kostner

### **Novartis CSANZ Posters**

Access the Novartis CSANZ posters presented at the Annual Scientific Meeting of the Cardiac Soceity of Australia and New Zealand (CSANZ)

### **Mini Oral Presentation**

**Title:** LDL-C target attainment and statin use in patients with ASCVD, familial hypercholesterolemia, and those otherwise at moderate/high-risk of ASCVD in Australian general practice (SCOPE-GP)

Paper No. 929

Session Details: 06. Prevention

Mini Oral Session Time: 12:30 - 1:40pm Presentation Time: 12:50 - 12:55pm

**Presentation Order: 5** 

Presenting Author: Prof Gerald Watts

### **Dedicated Poster Session Time**

5:40 - 6:30pm

#### **Posters**

**Title:** Real-world effectiveness, adherence and safety of inclisiran treatment in Belgian

patients with atherosclerotic cardiovascular disease: The BE. REAL registry

Paper No: 478

Presenting Author: A/Prof John Amerena

**Title:** Effect of mild hepatic impairment on the pharmacokinetics of Pelacarsen

Paper No: 189

Presenting Author: A/Prof Timothy Tan

Title: Lp(a) testing and LDL-C levels among Australian ASCVD patients in 2022: a cross-

sectional study from the Advara heartcare network (PREVAIL)

Paper No: 265

Presenting Author: Dr Jason Kaplan

**Source URL:** https://www.pro.novartis.com/au-en/csanz-2025